SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
"Innovation in the Pharmaceutical Industry".
0 references·16 citing·56 second hop
"Innovation in the Pharmaceutical Industry". (1978)"Innovation in the Pharmaceutical Industr…A Multilevel Investigation of Individual- and Unit-Level Human Capital Complementarities (2013)A Multilevel Investigation of…The Competitive Implications of Certifications: The Effects of Scientific and Regulatory Certifications on Entries into New Technical Fields (2012)The Competitive Implications …Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration (2007)Strategic Entry Deterrence an…Regulating pharmaceuticals in Europe : striving for efficiency, equity and quality (2004)Regulating pharmaceuticals in…Price Competition in Pharmaceuticals: The Case of Anti‐infectives (2004)Price Competition in Pharmace…The determinants of pharmaceutical research and development expenditures (2001)The determinants of pharmaceu…New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms (2000)New Drug Innovation and Pharm…Moral hazard in physician prescription behavior (2000)Moral hazard in physician pre…Global Competitiveness in Pharmaceuticals: A European Perspective (2000)Global Competitiveness in Pha…Generic take-up in the pharmaceutical market following patent expiry (2000)Generic take-up in the pharma…Chapter 25 The pharmaceutical industry (2000)Chapter 25 The pharmaceutical…The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research (1999)The Diffusion of Science-Driv…The Evolution of Knowledge and the Dynamics of an Industry Network (1997)The Evolution of Knowledge an…Direct Estimation of Synergy: A New Approach to the Diversity-Performance Debate (1993)Direct Estimation of Synergy:…Pricing, Patent Loss and the Market For Pharmaceuticals (1991)Pricing, Patent Loss and the …The political economy of the pharmaceutical industry. (1986)The political economy of the …Industrial research and technological innovation (1968)Social and Private Rates of Return from Industrial Innovations* (1977)The Rate of Obsolescence Of Knowledge, Research Gestation Lags, and the Private Rate of Return to Research Resources (1979)Asymmetric International Minimum Quality Standards and Vertical Differentiation (1995)Innovation and firm‐level persistent profitability: a Schumpeterian framework (2001)Absorptive Capacity: A New Perspective on Learning and Innovation (1990)Exploration and Exploitation in Organizational Learning (1991)Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)Public Research and Industrial Innovation: A Comparison of US and European Innovation Systems in the Life Sciences (2003)Dynamic competition in pharmaceuticals (2004)No pills for poor people? Understanding the disembowelment of India’s patent regime (2005)The economics of moral hazard: comment (1982)The price of innovation: new estimates of drug development costs (2003)UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE (2003)Competition in off-patent drug markets: Issues, regulation and evidence (2008)What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries (2008)Pharmaceutical policies in European countries in response to the global financial crisis (2011)A Computationally Efficient Quadrature Procedure for the One-Factor Multinomial Probit Model (1982)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing (2003)Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan (2008)Physician Agency and Adoption of Generic Pharmaceuticals (2012)Strategy, structure, and economic performance (1974)Strategy and Structure: (1986)From Competitive Advantage to Corporate Strategy (1989)Diversity, social identity, and performance: Emergent social dynamics in cross-functional teams. (1995)Analyzing Complementarities Using Software Stacks for Software Industry Acquisitions (2006)Determining the effects of lean production and servitization of manufacturing on sustainable performance (2020)Good News and Bad News: Representation Theorems and Applications (1981)The Theory of Industrial Organization (1988)Theory of Industrial Organization. (1989)The Relative Importance of Actual and Potential Competition: Empirical Evidence From the Pharmaceuticals Market (2003)Games Hospitals Play: Entry Deterrence in Hospital Procedure Markets (2005)Competition in Health Care Markets11We wish to thank participants at the Handbook of Health Economics meeting in Lisbon, Portugal, Pedro Pita Barros, Rein Halbersman, and Cory Capps for helpful comments and suggestions. Misja Mikkers, Rein Halbersma, and Ramsis Croes of the Netherlands Healthcare Authority graciously provided data on hospital and insurance market structure in the Netherlands. David Emmons kindly provided aggregates of the American Medical Association's calculations of health insurance market structure. Leemore Dafny was kind enough to share her measures of market concentration for the large employer segment of the US health insurance market. All opinions expressed here and any errors are the sole responsibility of the authors. No endorsement or approval by any other individuals or institutions is implied or should be inferred. (2011)Investment and Research and Development at the Firm Level: Does the Source of Financing Matter? (1992)Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)Capital-Market Imperfections and Investment (1997)The Distribution of Sales Revenues from Pharmaceutical Innovation (2000)Profits, R&D, and innovation—a model and a test (2012)Entry Deterrence in the Ready-to-Eat Breakfast Cereal Industry (1978)Handbook of Industrial Organization (1989)Entry and Competition in Concentrated Markets (1991)Pharmaceutical pricing policies in a global market (2008)Pharmaceutical Prices under Regulation: Tiered Co-payments and Reference Pricing in Germany (2012)Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs (2013)Firm Resources and Sustained Competitive Advantage (1991)Self-Efficacy: The Exercise of Control (1999)Firm resources and sustained competitive advantage (2004)The influence of internal HRM activity fit on the dynamics within the “black box” (2015)A conceptual framework for leveraging team composition decisions to build human capital (2017)Human Capital Resources: Reviewing the First Decade and Establishing a Foundation for Future Research (2022)Monopolistic Competition with Outside Goods (1979)Limit Pricing and Entry under Incomplete Information: An Equilibrium Analysis (1982)Generic Competition in the US Pharmaceutical Industry (2006)The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing (2006)A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION* (2010)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 1986The political economy of the pharmaceutical industry.169 cited
  • 2000Moral hazard in physician prescription behavior164 cited
  • 2004Regulating pharmaceuticals in Europe : striving for efficiency, equity and quality162 cited
  • 1991Pricing, Patent Loss and the Market For Pharmaceuticals157 cited
  • 2000Global Competitiveness in Pharmaceuticals: A European Perspective135 cited
  • 2004Price Competition in Pharmaceuticals: The Case of Anti‐infectives118 cited
  • 2007Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration118 cited
  • 1993Direct Estimation of Synergy: A New Approach to the Diversity-Performance Debate108 cited
  • 2013A Multilevel Investigation of Individual- and Unit-Level Human Capital Complementarities98 cited
  • 2001The determinants of pharmaceutical research and development expenditures97 cited
  • 2000Generic take-up in the pharmaceutical market following patent expiry92 cited
  • 2012The Competitive Implications of Certifications: The Effects of Scientific and Regulatory Certifications on Entries into New Technical Fields87 cited
  • 2000New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms78 cited
  • 1999

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research
77 cited
  • 2000Chapter 25 The pharmaceutical industry76 cited
  • 1997The Evolution of Knowledge and the Dynamics of an Industry Network72 cited